Another B-Cell Drug for Lupus Hits the Mark Phase III results put obinutuzumab in line for approval

" #Obinutuzumab ( #Gazyva ) appears set to add systemic #lupus erythematosus ( #SLE ) to its list of approved indications, as results from a phase III trial showed it was significantly more effective than placebo, with no new safety concerns.": buff.ly/WWFikk5

via @medpagetoday.com
#BCell #MedSky

A study of #Roche's #Gazyva has raised the prospect of a first approved therapy for primary membranous #nephropathy (pMN), a rare autoimmune #kidneydisorder.

buff.ly/sh4CQSZ

ロシュ、全身性エリテマトーデス（SLE）における抗CD20抗体オビヌツズマブ（ガザイバ）の第3相で主要評価項目を達成 | STELLANEWS.LIFE ロシュの抗CD20抗体オビヌツズマブ（ガザイバ）は、第3相ALLEGORY試験で全身性エリテマトーデス（SLE）の疾患活動性を有意に低下。主要評価項目および副次評価項目を達成し、安全性は既知の範囲内で新たな懸念は確認されなかった。

Roche’s Gazyva (obinutuzumab) meets all primary and secondary endpoints in Phase 3 ALLEGORY trial for systemic lupus erythematosus (SLE).

stellanews.life/technology_c...

#Gazyva #SLE #Lupus #Obinutuzumab #CD20 #AutoimmuneDiseases #Roche #ALLEGORYtrial

Roche's Gazyva breaks new ground in lupus Already approved for kidney damage in lupus, Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder.

Already approved for #lupusnephritis, #Roche's #Gazyva could be heading for broader use in the potentially life-threatening #autoimmune disorder after clearing a phase 3 trial.

pharmaphorum.com/news/roches-...

FDA approved #obinutuzumab #Gazyva for the treatment of #SLE #lupus nephritis when used with other standard therapies!

Complete renal responses: higher than standard therapies.

Studies show deep tissue B-cell depletion.

FDA Greenlights Gazyva® for Lupus Nephritis Treatment: A Major Step Forward The FDA has approved Gazyva® for lupus nephritis in adults, illustrating an important advancement in treatment options against this debilitating condition.

FDA Greenlights Gazyva® for Lupus Nephritis Treatment: A Major Step Forward #USA #Washington #Lupus_Nephritis #Genentech #GAZYVA

Lupus Research Alliance Celebrates FDA Approval of Gazyva for Lupus Nephritis Treatment The Lupus Research Alliance expresses gratitude for the FDA's approval of Gazyva, marking a significant advancement in lupus nephritis management.

Lupus Research Alliance Celebrates FDA Approval of Gazyva for Lupus Nephritis Treatment #USA #New_York #Lupus_Nephritis #Genentech #GAZYVA

Lupus Nephritis Market Expected to Grow at 8.5% CAGR Over the Next Decade The lupus nephritis market is projected to expand significantly, driven by increased prevalence and innovative therapies, reaching a size of $1.8 billion by 2024.

Lupus Nephritis Market Expected to Grow at 8.5% CAGR Over the Next Decade #USA #Las_Vegas #DelveInsight #Lupus_Nephritis #GAZYVA